Capricor Therapeutics Stock Price, News & Analysis (NASDAQ:CAPR)

$1.70 -0.08 (-4.49 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$1.70
Today's Range$1.67 - $1.85
52-Week Range$0.63 - $4.25
Volume290,412 shs
Average Volume393,446 shs
Market Capitalization$43.71 million
P/E Ratio-2.58
Dividend YieldN/A
Beta-3.76

About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CAPR
CUSIPN/A
Phone+1-310-3583200

Debt

Debt-to-Equity RatioN/A
Current Ratio0.91%
Quick Ratio0.91%

Price-To-Earnings

Trailing P/E Ratio-2.57575757575758
Forward P/E Ratio-2.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$4 million
Price / Sales10.93
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-8.95

Profitability

Trailing EPS($0.66)
Net Income$-18,800,000.00
Net Margins-464.56%
Return on EquityN/A
Return on Assets-82.11%

Miscellaneous

Employees40
Outstanding Shares25,710,000

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The biotechnology company earned $0.31 million during the quarter, compared to the consensus estimate of $1 million. The business's revenue was down 58.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.29) EPS. View Capricor Therapeutics' Earnings History.

When will Capricor Therapeutics make its next earnings announcement?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Capricor Therapeutics.

Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2018?

2 brokers have issued 12 month target prices for Capricor Therapeutics' shares. Their predictions range from $2.15 to $6.50. On average, they anticipate Capricor Therapeutics' share price to reach $4.33 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:

  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

How do I buy Capricor Therapeutics stock?

Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of Capricor Therapeutics stock can currently be purchased for approximately $1.70.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $43.71 million and generates $4 million in revenue each year. The biotechnology company earns $-18,800,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 Wilshire Blvd Fl 2, BEVERLY HILLS, CA 90211-2606, United States. The biotechnology company can be reached via phone at +1-310-3583200 or via email at [email protected]


MarketBeat Community Rating for Capricor Therapeutics (CAPR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Capricor Therapeutics (NASDAQ:CAPR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.33$4.33$6.88$9.33
Price Target Upside: 336.87% upside336.87% upside595.29% upside1,262.73% upside

Capricor Therapeutics (NASDAQ:CAPR) Consensus Price Target History

Price Target History for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017HC WainwrightBoost Price TargetBuy -> Buy$2.15 -> $6.50N/AView Rating Details
7/22/2017Rodman & RenshawReiterated RatingBuy$2.15N/AView Rating Details
10/20/2016Roth CapitalSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Capricor Therapeutics (NASDAQ:CAPR) Earnings History and Estimates Chart

Earnings by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ CAPR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.19)N/AView Earnings Details
11/8/2017Q3 2017($0.19)($0.12)$1.00 million$0.31 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.18)($0.16)$1.10 million$1.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)($0.17)$0.87 million$0.88 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.30)($0.14)$1.05 million$0.91 millionViewN/AView Earnings Details
11/10/2016Q316($0.27)($0.29)$1.12 million$0.75 millionViewN/AView Earnings Details
8/15/2016Q2($0.24)($0.26)$1.22 million$1.13 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 million$1.22 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 million$1.12 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 million$1.32 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 million$1.29 millionViewN/AView Earnings Details
5/12/2015Q1 2015($0.14)($0.23)$1.10 million$1.79 millionViewN/AView Earnings Details
3/18/2015Q4 2014($0.14)($0.16)$1.30 million$1.40 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.22)($0.13)$1.30 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.10)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.50)ViewN/AView Earnings Details
6/21/2013Q4 2012($11.50)ViewN/AView Earnings Details
8/14/2012Q2 2012($1.00)($0.40)ViewN/AView Earnings Details
5/15/2012Q1 2012($1.00)($0.95)ViewN/AView Earnings Details
11/14/2011Q3 2011($1.00)($1.45)ViewN/AView Earnings Details
8/15/2011Q2 2011($1.00)($1.25)ViewN/AView Earnings Details
5/16/2011Q1 2011($1.00)($1.70)ViewN/AView Earnings Details
3/14/2011Q4 2010($2.00)($1.15)ViewN/AView Earnings Details
11/12/2010Q3 2010($2.50)($2.60)ViewN/AView Earnings Details
8/16/2010Q2 2010($3.50)($2.30)ViewN/AView Earnings Details
5/14/2010Q1 2010($3.00)($3.50)ViewN/AView Earnings Details
3/3/2010Q4 2009($2.50)($2.90)ViewN/AView Earnings Details
11/12/2009Q3 2009($2.50)($4.00)ViewN/AView Earnings Details
8/13/2009Q2 2009($3.50)($5.20)ViewN/AView Earnings Details
5/14/2009Q1 2009($6.00)($3.70)ViewN/AView Earnings Details
3/9/2009Q4 2008($7.00)($6.15)ViewN/AView Earnings Details
11/13/2008Q3 2008($8.00)($6.90)ViewN/AView Earnings Details
8/14/2008Q2 2008($7.85)ViewN/AView Earnings Details
5/15/2008Q1 2008($6.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Capricor Therapeutics (NASDAQ:CAPR) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.7 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Capricor Therapeutics (NASDAQ:CAPR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 3.87%
Insider Trades by Quarter for Capricor Therapeutics (NASDAQ:CAPR)
Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ CAPR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2017Louis ManzoDirectorBuy10,000$3.10$31,000.00138,384View SEC Filing  
5/9/2017Sinai Medical Center CedarsMajor ShareholderBuy1,145,161$3.10$3,549,999.104,049,959View SEC Filing  
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.002,904,798View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.002,030View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.0011,156View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.002,100View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.402,592,298View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.005,950View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.003,173,354View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Capricor Therapeutics (NASDAQ CAPR) News Headlines

Source:
DateHeadline
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based TechnologiesCapricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
finance.yahoo.com - January 16 at 8:58 AM
 Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 30 at 7:46 AM
Capricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head ReviewCapricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head Review
www.americanbankingnews.com - December 29 at 9:30 AM
Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - December 18 at 8:58 AM
ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:23 PM
Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)
www.prnewswire.com - December 13 at 5:01 PM
BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome TechnologyBRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology
www.reuters.com - December 13 at 9:05 AM
Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome TechnologyCapricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
finance.yahoo.com - December 13 at 9:05 AM
BRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan AwardBRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan Award
www.reuters.com - December 12 at 5:11 PM
CAPRICOR THERAPEUTICS, INC. - StreetInsider.comCAPRICOR THERAPEUTICS, INC. - StreetInsider.com
www.streetinsider.com - December 12 at 10:30 AM
Stock Review for Biotechs Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and ... - PR Newswire (press release)Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - December 11 at 5:01 PM
Stock Review for Biotechs Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and BioDelivery SciencesStock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and BioDelivery Sciences
www.bizjournals.com - December 11 at 9:31 AM
Capricor Therapeutics (CAPR) versus Its Rivals Critical ContrastCapricor Therapeutics (CAPR) versus Its Rivals Critical Contrast
www.americanbankingnews.com - December 8 at 7:46 PM
Zacks: Analysts Set $6.50 Target Price for Capricor Therapeutics Inc (CAPR)Zacks: Analysts Set $6.50 Target Price for Capricor Therapeutics Inc (CAPR)
www.americanbankingnews.com - December 8 at 3:48 AM
How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?
finance.yahoo.com - December 6 at 5:56 PM
Critical Contrast: Capricor Therapeutics (CAPR) & Its RivalsCritical Contrast: Capricor Therapeutics (CAPR) & Its Rivals
www.americanbankingnews.com - December 5 at 3:32 AM
Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular DystrophyActive-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy
www.finanznachrichten.de - December 1 at 4:15 PM
Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular DystrophyWired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy
finance.yahoo.com - December 1 at 4:15 PM
ETFs with exposure to Capricor Therapeutics, Inc. : November 30, 2017ETFs with exposure to Capricor Therapeutics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:49 PM
 Capricor Therapeutics, Inc. (CAPR) Given $6.50 Consensus Target Price by Analysts Capricor Therapeutics, Inc. (CAPR) Given $6.50 Consensus Target Price by Analysts
www.americanbankingnews.com - November 30 at 2:18 PM
Capricor Soars on FDA Nod - Baystreet.caCapricor Soars on FDA Nod - Baystreet.ca
www.baystreet.ca - November 30 at 9:00 AM
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 - PR Newswire (press release)Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 - PR Newswire (press release)
www.prnewswire.com - November 29 at 5:07 PM
Capricor Therapeutics Inc (CAPR) Shares Soar on Back of FDA Investigational New Drug ClearanceCapricor Therapeutics Inc (CAPR) Shares Soar on Back of FDA Investigational New Drug Clearance
finance.yahoo.com - November 29 at 5:07 PM
Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:09 AM
Capricor Therapeutics stock rises 18% on FDA clearance for DMD clinical trialCapricor Therapeutics stock rises 18% on FDA clearance for DMD clinical trial
finance.yahoo.com - November 29 at 10:09 AM
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
finance.yahoo.com - November 29 at 8:50 AM
Capricor: Risks Outweigh HOPE - Seeking AlphaCapricor: Risks Outweigh 'HOPE' - Seeking Alpha
seekingalpha.com - November 25 at 3:47 PM
Capricor Therapeutics (CAPR) and The Competition Head-To-Head ComparisonCapricor Therapeutics (CAPR) and The Competition Head-To-Head Comparison
www.americanbankingnews.com - November 25 at 1:22 AM
Capricor Therapeutics (CAPR) Updates On Results from the HOPE-Duchenne Clinical Trial (12 months) - SlideshowCapricor Therapeutics (CAPR) Updates On Results from the HOPE-Duchenne Clinical Trial (12 months) - Slideshow
seekingalpha.com - November 16 at 5:24 PM
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricors Investigational Cell TherapySignificant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
finance.yahoo.com - November 16 at 12:25 PM

SEC Filings

Capricor Therapeutics (NASDAQ:CAPR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.